Terry Rosen is Chief Executive Officer and co-founder of Arcus Biosciences, a biotechnology company focused on developing cancer therapies designed to counter tumor-induced immunosuppression and enhance anti-tumor immune responses. Rosen co-founded Arcus following his leadership of Flexus Biosciences, which was acquired by Bristol Myers Squibb, and has built Arcus around a science-driven approach to immuno-oncology that emphasizes rational combination strategies and platform-based discovery.
Under his leadership, Arcus has established a diversified oncology pipeline and formed strategic collaborations that support the development of novel immunotherapies aimed at overcoming resistance to existing cancer treatments. Rosen previously held senior leadership roles at Amgen, Pfizer, and Abbott Laboratories, bringing deep experience across discovery, development, and corporate strategy. He serves on several scientific and industry boards, including the Salk Institute Board of Trustees, reflecting his broader influence in biotechnology innovation and governance.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
